Resolvines as potential new therapeutic targets for the treatment of visceral hypersensitivity KU Leuven
About 10-20 % of individuals worldwide suffer from Irritable Bowel Syndrome (IBS), which is one of the most common gastrointestinal diseases in the western world. Characteristic symptoms vary from patient to patient but include chronic discomfort and abdominal pain associated with altered bowel habits in the absence of an organic cause. About 60% of IBS patients suffer from increased abdominal pain perception or visceral hypersensitivity ...